Penicillin V

Mild-to-moderately severe susceptible streptococcal infections without bacteremia, respiratory pneumococcal infections, proven penicillin-sensitive mild staphylococcal skin/soft-tissue infections and fusospirochetal oropharyngeal infection. Culture/susceptibility and local epidemiology guide selection; many staphylococci produce penicillinase. Acute severe pneumonia, empyema, bacteremia, pericarditis, meningitis or arthritis should not be treated with penicillin V.

Label secondary prophylaxis after rheumatic fever/chorea remains a distinct clinical indication. Its endocarditis prophylaxis cites a 1984 AHA/ADA statement and lists an old oral penicillinV algorithm. The current AHA 2024 card instead restricts dental prophylaxis to selected highest-risk cardiac conditions and lists a single preprocedure amoxicillin regimen, not penicillinV. Do not execute the old label endocarditis dose; verify contemporary cardiology/dental guidance.

Children: 250 mg twice or three times daily for 10 days. Adolescents/adults: 250 mg four times daily or 500 mg twice daily for 10 days. Confirm GAS by positive rapid antigen test or culture; do not treat viral pharyngitis. CDC recommends culture confirmation after a negative rapid test in symptomatic children older than 3. This guideline-specific regimen differs from some older label interval wording.

Streptococcal upper-respiratory/scarlet-fever/erysipelas: 125–250 mg every 6–8 hours for 10 days. Pneumococcal respiratory infection: 250–500 mg every 6 hours until afebrile at least 2 days. Susceptible mild staphylococcal skin/soft-tissue or Vincent’s oropharyngeal infection: 250–500 mg every 6–8 hours, duration/response clinician-selected; necessary dental care accompanies gum infection. The label supplies no universal resistance-independent empiric course.

Label recurrent rheumatic fever/chorea prevention: 125–250 mg twice daily on a continuing basis, with patient-specific duration/eligibility. May take with meals, although empty-stomach blood levels are somewhat higher. Complete the prescribed course and interval; do not share or save antibiotics. No new automatic repeat-course or home IV regimen is supplied.

125 mg/5 mL (25 mg/mL) and 250 mg/5 mL (50 mg/mL); verify before calculating volume. Selected 100 mL bottle requires 75 mL water,200 mL bottle 150 mL, added in stages with vigorous shaking by the dispenser. Refrigerate after mixing/discard 14 days. Renal dysfunction delays excretion; the selected U.S. label supplies no numeric renal/hepatic algorithm, so individualized clinical assessment is required rather than a guessed percentage reduction.

Previous hypersensitivity reaction to any penicillin. Susceptibility, severity and oral-absorption limitations require separate treatment selection; lack of a contraindication does not make penicillin V suitable for invasive infection.

Selected U.S. label has no boxed warning. Its prominent anaphylaxis and C. difficile warnings remain clinically significant.

Nausea/vomiting, epigastric discomfort, diarrhea and black hairy tongue are reported. Allergy ranges from rash/urticaria/serum-sickness-like reactions to laryngeal edema and fatal anaphylaxis. Some severe hematologic, neurologic or renal reports mainly concern high-dose parenteral penicillin and are not incidence estimates for this oral product. Excess/accidental dosing requires medical/Poison Help review; no “safe overdose” threshold is given.

Comparable UK primary SmPC: probenecid reduces penicillinV excretion; penicillins can increase methotrexate toxicity. Review warfarin/INR control, oral typhoid-vaccine timing, and potassium-sparing drugs because hyperkalemia is possible. Nonenzymatic urine-glucose tests may be falsely positive. These are interaction assessments, not imported UK dose instructions or a blanket claim that ordinary noninducing antibiotics disable hormonal contraception.

U.S. label usual infection regimens are written for adults/children ≥ 12. Current CDC GAS regimen supplies a separate pediatric course, not a universal dose for every infant infection. Excretion is delayed in neonates/young infants and renal dysfunction. Older patients need organ-function/co-therapy assessment; no numeric age-only adjustment is supplied.

The selected U.S. label gives no dedicated modern reproductive-risk summary. Comparable manufacturer UK SmPC supports pregnancy use when clinically needed with caution; trace milk exposure can alter infant flora or cause allergy/sensitization. Discuss indication and infant symptoms rather than claim no risk or copy parenteral-penicillin advice.

Renal impairment can substantially delay excretion. Evaluate kidney function, potassium load, infection response and tolerability; selected U.S. label does not define an eGFR-based adjustment or liver-dose formula. Potassium per tablet: 250 mg contains 0.71 mEq;500 mg 1.43 mEq. This is clinically relevant ingredient content, not the antibacterial dose.

Bactericidal during active multiplication through cell-wall synthesis inhibition; penicillinase-producing organisms resist. Oral absorption is incomplete; U.S. label protein binding about 80% with rapid renal elimination and delayed excretion in renal dysfunction. Comparable UK SmPC reports an approximately 30-minute half-life, prolonged in renal failure. No serum target or CNS-infection regimen is inferred.

Check microbiologic diagnosis/susceptibility when indicated, clinical response and oral intake. Assess allergy, significant diarrhea/superinfection and renal/potassium context. Obtain cultures/labs when clinically warranted; the label’s blanket post-strep culture language is older provenance and should be reconciled with current diagnosis/follow-up guidance rather than presented as a mandatory universal test.

Take exactly as prescribed and finish the indicated course; never treat a viral cold or share leftovers. Verify liquid concentration and measured dose, keep mixed solution refrigerated and discard 14 days. Breathing difficulty/swelling/collapse needs emergency care; watery/bloody diarrhea or fever/cramps warrants prompt review even after finishing. Report poor oral intake/vomiting or lack of improvement.

Selected 500 mg mottled white/off-white oval scored tablet: 9/3 across one face,1174 reverse; NDC 62135-099-40,40-tablet bottle. Verify actual package; not evidence of stock.

Tablets 250 and 500 mg, corresponding 400,000 and 800,000 penicillinV units. Oral solutions 125 or 250 mg per 5 mL after reconstitution. Selected FDA ANDA 060711 tablets and ANDA 060456 solutions list Prescription products. Ingredient-potassium content and microbiological units are not alternative routes or mg-for-mg substitutes for penicillin G preparations.

Tablets/dry powder 20–25°C, tightly closed containers; dispense tablets with required child-resistant closure. Add water only at dispensing. Mixed solution must be refrigerated and discarded after 14 days. Keep children away and follow actual bottle expiry and concentration.